Personalis, Inc. (NASDAQ:PSNL) Receives $14.25 Consensus Target Price from Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned a consensus rating of “Hold” from the nine research firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.25.

Several analysts recently commented on the stock. Morgan Stanley increased their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Zacks Research cut shares of Personalis from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Needham & Company LLC downgraded shares of Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Finally, BTIG Research raised their price target on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th.

Personalis Trading Up 2.4%

Personalis stock opened at $14.50 on Friday. The business’s fifty day simple moving average is $12.45 and its two-hundred day simple moving average is $9.37. Personalis has a 12 month low of $4.42 and a 12 month high of $16.39. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -13.30 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. On average, equities research analysts predict that Personalis will post -1.07 EPS for the current year.

Insider Buying and Selling at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares in the company, valued at $3,558,668.88. The trade was a 29.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 435,032 shares of company stock worth $5,599,929. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Personalis

Hedge funds have recently bought and sold shares of the business. Merck & Co. Inc. purchased a new stake in shares of Personalis during the 2nd quarter valued at about $188,202,236,000. T. Rowe Price Investment Management Inc. raised its holdings in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after purchasing an additional 7,896,714 shares during the last quarter. BlackRock Inc. bought a new position in Personalis during the second quarter valued at approximately $94,905,000. AIGH Capital Management LLC bought a new position in Personalis during the second quarter valued at approximately $22,981,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Personalis by 1,332.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after purchasing an additional 1,347,439 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.